Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Genmab A/S: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Genmab A/S
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
Weaknesses: Genmab A/S
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Rating Financials

Genmab A/S SectorDenmark

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Genmab A/S SectorDenmark

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Genmab A/S SectorDenmark

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Genmab A/S SectorDenmark

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Genmab A/S SectorDenmark

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
16.2B
A
50.04B
A
48.62B
AAA
25.57B -
A
- -
23.32B - - - -
17.89B
AAA
14.97B
B
14.58B - - - -
13.47B -
AA
- -
12.89B
BB
Average 23.76B
A
Weighted average by Cap.
A